Domainex Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Private

  • Employees
  • 108

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 6

Domainex General Information

Description

Provider of drug discovery services intended to offer research facilities for developing advanced medicines. The company's services use biochemical binding technology for the development of oncology drugs, including inhibitors of the kinases and epigenetics related lysine methyltransferases, enabling healthcare professionals to tackle drug discovery problems against a wide range of drug targets.

Contact Information

Website
www.domainex.co.uk
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Chesterford Research Park, Churchill Building
  • Little Chesterford, Essex
  • Saffron Walden CB10 1XL
  • England, United Kingdom
+44 01223 000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Domainex Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Secondary Transaction - Private 17-Jan-2019 000 Completed Profitable
10. Grant 23-Jan-2018 00000 000 Completed Profitable
9. Secondary Transaction - Private 08-Dec-2017 000 Completed Profitable
8. Grant 01-Oct-2015 00000 000 Completed Profitable
7. Secondary Transaction - Private 09-Apr-2015 000 Completed Profitable
6. Grant 09-Jul-2014 00.000 000 Completed Profitable
5. Later Stage VC 14-Feb-2013 00.000 000 000.00 Completed Profitable
4. Later Stage VC 17-Feb-2010 00.000 00.000 000.00 Completed Profitable
3. Later Stage VC (Series A) 23-Apr-2008 $2.06M $3.16M Completed Startup
2. Later Stage VC 01-Jan-2007 $706K $1.1M Completed Startup
To view Domainex’s complete valuation and funding history, request access »

Domainex Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
B Ordinary 00,000 00.000000 000.00 000.00 00 000.00 0.000
B Ordinary 00,000 00.000000 000.00 000.00 00 000.00 00.000
A Ordinary 12,000 $0.015762 $47.29 $47.29 1x $47.29 2.62%
A Preferred 14,365 $0.015762 $22.07 $22.07 1x $22.07 3.14%
To view Domainex’s complete cap table history, request access »

Domainex Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Provider of drug discovery services intended to offer research facilities for developing advanced medicines. The company
Drug Discovery
Saffron Walden, United Kingdom
108 As of 2023
000
00000000000 000

000000

iam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo con
0000 000000000
Nottingham, United Kingdom
0000 As of 0000
000000000

000 00

mpor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis
0000 000000000
Princeton, NJ
00 As of 0000
0000
0000000000 0 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Domainex Competitors (69)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sygnature Discovery Private Equity-Backed Nottingham, United Kingdom 0000 000000000
000 00000000000 Venture Capital-Backed Princeton, NJ 00 0000 0000000000 0 0000
000000000 000000 Corporate Backed or Acquired Montreal, Canada 0 000000&0
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 00000000
0000000 0000000000 Venture Capital-Backed Cambridge, United Kingdom 00 00000 0000000000 00000
You’re viewing 5 of 69 competitors. Get the full list »

Domainex Patents

  • 36

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 3

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Domainex Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2018224359-A1 5-(pyrimidin-4-yl)-2-(pyrrolidin-1-yl)nicotinonitrile compounds as ikke, tbk1 and/or sik2 kinases inhibitors Active 23-Feb-2017 0000000000
AU-2018224359-B2 5-(pyrimidin-4-yl)-2-(pyrrolidin-1-yl)nicotinonitrile compounds as ikke, tbk1 and/or sik2 kinases inhibitors Inactive 23-Feb-2017 0000000000 0
CA-3054343-A1 5-(pyrimidin-4-yl)-2-(pyrrolidin-1-yl)nicotinonitrile compounds as ikke, tbk1 and/or sik2 kinases inhibitors Pending 23-Feb-2017 0000000000
EP-3585776-A1 5-(pyrimidin-4-yl)-2-(pyrrolidin-1-yl)nicotinonitrile compounds as ikke, tbk1 and/or sik2 kinases inhibitors Active 23-Feb-2017 0000000000
EP-3585776-B1 5-(pyrimidin-4-yl)-2-(pyrrolidin-1-yl)nicotinonitrile compounds as ikke, tbk1 and/or sik2 kinases inhibitors Active 23-Feb-2017 C07D401/14
To view Domainex’s complete patent history, request access »

Domainex Executive Team (16)

Name Title Board Seat Contact Info
Thomas Mander Ph.D Chief Executive Officer & Board Member
David Cronk Chief Operating Officer & Chief Of Staff
Laurence Pearl Ph.D Co-Founder, Chief Scientific Officer & Board Member
Robina Akhtar Financial Controller
Ralph Stephen Harris Deputy Chairman
You’re viewing 5 of 16 executive team members. Get the full list »

Domainex Board Members (11)

Name Representing Role Since
Edward Beckett Longbow Capital Board Member 000 0000
Edward Littler Ph.D Self Chairman 000 0000
Frank Bury Self Board Member 000 0000
Judith Hills Ph.D Domainex Non-Executive Director 000 0000
Laurence Pearl Ph.D Domainex Co-Founder, Chief Scientific Officer & Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Domainex Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Domainex Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Innovate UK Government 000 0000 000000 0
Medical Research Council Corporation 000 0000 000000 0
Juno Capital Asset Manager Minority 000 0000 000000 0
UCL Business University Minority 000 0000 000000 0
Takeda Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial